A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout
第4相
完了
NCT06229145
| 対象疾患 | Gout |
|---|
| 相 | 第4相 |
|---|
| スポンサー | Amgen |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 262 名 |
|---|
| 介入（薬剤） | Pegloticase, Methotrexate |
|---|
| 開始日 | 2024年3月18日 |
|---|
| 完了日 | 2025年7月30日 |
|---|
| 結果公開日 | 2026年7月1日 |
|---|
概要
The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus pegloticase Q2W with MTX, followed by a 24-week open-label extension of pegloticase Q4W with MTX, in participants with uncontrolled refractory gout. The main objective of the study is to evaluate the effect of pegloticase 16 mg administered Q4W with MTX versus pegloticase 8 mg administered Q2W with MTX, on the response rate during Month 6, as measured by the sustained normalization of sUA to \< 6 mg/dL for at least 80% of the time.
Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6
Month 6 (Weeks 20, 21, 22, 23, and 24) · percentage of participants
| Pegloticase 8mg Q2W + MTX | 70.8 percentage of participants |
|---|
| Pegloticase 16mg Q4W + MTX | 56.5 percentage of participants |
|---|
| p-value | 0.10 |
|---|
| Response rate difference | 12.7 (95% CI 1.2–24.1) |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。